(UroToday.com) At the European Association of Urology 2021 annual meeting, Dr. Vikram M. Narayan, from Emory University presented results of several key subgroup analyses from the recently published trial assessing nadofaragene firadenovec in BCG-unresponsive NMIBC. The goals of treatment of NMIBC are to reduce recurrence and prevent progression, however, despite optimal treatment, ≥50% of patients who demonstrated an initial response to BCG will experience recurrence and progression and become BCG-unresponsive. With limited treatment options, there is an unmet medical need for local, effective, bladder-preserving treatment options.